Company Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Avacta Group Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 11:35:29 2024-05-31 am EDT			5-day change	1st Jan Change
40.4 ^GBX	-6.05%		-8.39%	-65.32%

May. 23	Windward wins deal; Kodal progresses at Bougouni	AN
May. 23	Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial	CI

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Number of employees: 120

GBP in Million	2022	Weight	2023	Weight	Delta
Diagnostics 91.2 %	4	43.2 %	21	91.2 %	+407.96%
Therapeutics 8.8 %	5	56.8 %	2	8.8 %	-62.51%

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 54.8 %	3	26.2 %	13	54.8 %	+403.55%
France 17.7 %	1	13.4 %	4	17.7 %	+217.90%
Rest of Europe 15.9 %	0	1.6 %	4	15.9 %	+2,234.18%
South Korea 8.8 %	5	56.8 %	2	8.8 %	-62.51%
Rest of World 2.6 %	0	0.1 %	1	2.6 %	+8,657.14%
North America 0.1 %	0	1.9 %	0	0.1 %	-88.27%

Managers	Title	Age	Since
Tony Gardiner DFI	Director of Finance/CFO	53	16-01-03
Matt Johnson CTO	Chief Tech/Sci/R&D Officer	-	13-09-15
Michael Vinegrad IRO	Public Communications Contact	-	14-05-31
Neil Bell PRN	Corporate Officer/Principal	-	20-06-30
Simon Bennett PRN	Corporate Officer/Principal	-	Dec. 18

Members of the board	Title	Age	Since
Trevor Nicholls BRD	Director/Board Member	67	13-08-01
Tony Gardiner DFI	Director of Finance/CFO	53	16-01-03
Paul Fry BRD	Director/Board Member	58	20-02-02
Eliot Forster CHM	Chairman	58	18-06-10
Mark Goldberg BRD	Director/Board Member	69	21-08-17
Shaun Chilton BRD	Director/Board Member	57	23-06-18
Christina Coughlin CEO	Chief Executive Officer	54	22-03-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	359,042,104	253,687,359 ( 70.66 %)	0	70.66 %

Name	Equities	%	Valuation
Hargreaves Lansdown Asset Management Ltd. 6.439 %	23,119,000	6.439 %	13 M p
Jarvis Investment Management Ltd. 5.980 %	21,472,000	5.980 %	12 M p
Conifer Management LLC 3.302 %	11,854,734	3.302 %	7 M p
Baillie Gifford & Co. 2.820 %	10,124,371	2.820 %	6 M p
IG Markets Ltd. 2.217 %	7,961,000	2.217 %	5 M p
HSBC Global Asset Management (UK) Ltd. 1.683 %	6,043,000	1.683 %	3 M p
Unicorn Asset Management Ltd. 1.198 %	4,300,000	1.198 %	2 M p
Premier Fund Managers Ltd. 1.017 %	3,652,532	1.017 %	2 M p
Avacta Group PLC JSOP 0.7746 %	2,781,000	0.7746 %	2 M p
HSBC Bank Plc (Market-Maker) 0.7300 %	2,621,000	0.7300 %	2 M p

Avacta Group Plc

Thorp Arch Estate Ash Way, Wetherby

LS23 7FA, Leeds

+44 1904 217 070

http://www.avacta.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.404 GBP

Average target price

0.8233 GBP

Spread / Average Target

+103.79%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AVACTA GROUP PLC	-65.32%	183M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs